Vasculitis: Clinical Trials

57 trials for Vasculitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

57 completed. 57 Phase 3, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 357Completed 57
Phase 26Completed 6

Follow Vasculitis: new trials by email Literature Review of Vasculitis trials Research Report on Vasculitis

Trials (filtered) newest first · largest first

All 57 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission
Secukinumab 300 mg, s.c., Placebo to match Secukinumab, s.c. - Giant Cell Arteritis
Phase 3CompletedNovartis Pharmaceuticals1512022-09-292026-02-27
Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)
Mepolizumab, cyclophosphamide/azathioprine, Placebo - Eosinophilic Granulomatosis With Polyangiitis
Phase 3CompletedAssistance Publique - Hôpitaux de Paris1022022-05-302026-10-01
Evaluation of Glucocorticoids Plus Rituximab in Patients With Newly-Diagnosed or Relapsing IgA Vasculitis
Rituximab Injection, placebo - IgA Vasculitis
Phase 3CompletedHopital Foch752022-03-112026-06-11
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
Secukinumab 300 mg, Placebo, Secukinumab 150 mg - Giant Cell Arteritis (GCA)
Phase 3CompletedNovartis Pharmaceuticals3542021-10-062026-03-31
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V
Niclosamide, Placebo, Ciclesonide - Covid19
Phase 2 / Phase 3CompletedCambridge University Hospitals NHS Foundation Trust22402021-02-192025-06-20
Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis
Rituximab, placebo - Microscopic Polyangiitis (MPA)
Phase 3CompletedAssistance Publique - Hôpitaux de Paris82020-10-242026-05-06
Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO
treatment - Arteritis, Giant Cell, Blindness and Low Vision
Phase 3CompletedCentre Hospitalier Universitaire de Nice82020-02-042026-06-18
MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial
Prednisone treatment, Tocilizumab treatment, Methotrexate treatment - Giant Cell Arteritis
Phase 3CompletedCentre Hospitalier Universitaire Dijon2302020-01-272026-10-30
Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease
IVIG, Aspirin, Prednisolone - Kawasaki Disease
Phase 3CompletedChildren's Hospital of Fudan University32082020-01-152026-04-16
A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
Upadacitinib, Corticosteroid (CS), Placebo - Giant Cell Arteritis (GCA)
Phase 3CompletedAbbVie4292019-01-242026-02-24
Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease
Infliximab, Cyclophosphamide - Behcet's Disease, Vasculitis
Phase 3CompletedAssistance Publique - Hôpitaux de Paris532018-05-252023-07-03
Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.
Rituximab, Azathioprine, Placebo-rituximab - Eosinophilic Granulomatosis With Polyangiitis
Phase 3CompletedAssistance Publique - Hôpitaux de Paris982018-03-072025-11-20
An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)
Tocilizumab - Giant Cell Arteritis
Phase 3CompletedHoffmann-La Roche32017-10-252020-09-04
Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis
Interferon Alfa-2A, Cyclosporine Pill - Behçet Disease, Uveitis
Phase 3CompletedPeking Union Medical College Hospital282017-06-302021-02-23
Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis
MMF, CYC, Glucocorticoids - Takayasu Arteritis
Phase 3CompletedChinese SLE Treatment And Research Group1382017-03-162023-08-30
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
Avacopan, Prednisone, Cyclophosphamide - ANCA-Associated Vasculitis
Phase 3CompletedAmgen3312017-03-152025-03-24
KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)
IVIG, Infliximab - Mucocutaneous Lymph Node Syndrome
Phase 3CompletedUniversity of California, San Diego1052017-02-172021-12-03
Rituximab in Eosinophilic Granulomatosis With Polyangiitis
Rituximab, Placebo-rituximab, Cyclophosphamide - Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Phase 3CompletedAssistance Publique - Hôpitaux de Paris1072016-12-052026-01-15
A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease
Infliximab - Behcet Disease
Phase 3CompletedJanssen Korea, Ltd., Korea332015-07-222019-10-17
Efficacy and Tolerability of Hirudoid Cream in Prophylaxis and Treatment Infusion Phlebitis
Hirudoid cream 0.3 % Mucopolysaccharide polysulfate, Placebo cream without active substance - Thrombophlebitis, Phlebitis
Phase 3CompletedMedinova AG1442015-05-012017-12-14

Showing 20 of 57. Sign in to see all of them.

Narrower conditions

Granulomatosis with Polyangiitis (13)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (11)  ·  Microscopic Polyangiitis (11)  ·  Giant Cell Arteritis (10)  ·  Mucocutaneous Lymph Node Syndrome (8)  ·  Behcet Syndrome (7)  ·  Churg-Strauss Syndrome (6)  ·  Thrombophlebitis (4)  ·  Phlebitis (3)  ·  Systemic Vasculitis (3)  ·  Lupus Erythematosus, Systemic (2)  ·  Panuveitis (2)  ·  Polymyalgia Rheumatica (2)  ·  Takayasu Arteritis (2)

Broader conditions

Cardiovascular Diseases (56)  ·  Vascular Diseases (55)  ·  Skin and Connective Tissue Diseases (50)  ·  Skin Diseases (49)  ·  Skin Diseases, Vascular (48)  ·  Immune System Diseases (34)  ·  Autoimmune Diseases (32)  ·  Nervous System Diseases (23)  ·  Brain Diseases (22)  ·  Central Nervous System Diseases (22)  ·  Cerebrovascular Disorders (21)  ·  Systemic Vasculitis (18)  ·  Hemic and Lymphatic Diseases (16)  ·  Lymphatic Diseases (14)

Interventions

Rituximab (10)  ·  Azathioprine (8)  ·  Cyclophosphamide (8)  ·  Infliximab (5)  ·  Immunoglobulins, Intravenous (4)  ·  Prednisone (4)  ·  Adrenal Cortex Hormones (3)  ·  Glucocorticoids (3)  ·  mepolizumab (3)  ·  secukinumab (3)  ·  tocilizumab (3)  ·  Cyclosporine (2)  ·  Interferon alpha-2 (2)  ·  Mycophenolic Acid (2)  ·  Prednisolone (2)

Sponsors

Assistance Publique - Hôpitaux de Paris (11)  ·  Cambridge University Hospitals NHS Foundation Trust (4)  ·  Novartis Pharmaceuticals (3)  ·  Amgen (2)  ·  Children's Hospital of Fudan University (2)  ·  GlaxoSmithKline (2)  ·  Hoffmann-La Roche (2)  ·  Tanabe Pharma Corporation (2)  ·  University of California, San Diego (2)  ·  University of Pennsylvania (2)  ·  AbbVie (1)  ·  Baxalta now part of Shire (1)  ·  Boston Children's Hospital (1)  ·  Centre Hospitalier Universitaire Dijon (1)  ·  Centre Hospitalier Universitaire de Nice (1)

Countries

France (26)  ·  United States (19)  ·  Italy (13)  ·  Canada (12)  ·  Germany (12)  ·  United Kingdom (12)  ·  Japan (9)  ·  Belgium (8)  ·  Spain (7)  ·  Sweden (7)  ·  Australia (6)  ·  Czechia (6)  ·  Netherlands (6)  ·  Norway (6)  ·  China (5)

Top investigators

Loic Guillevin, MD, PhD (3)  ·  David Jayne (2)  ·  John H. Stone, MD, MPH (2)  ·  Peter A Merkel, MD, MPH (2)  ·  Adriana H. Tremoulet, M.D. (1)  ·  Benilde Cosmi, MD PhD (1)  ·  Benjamin Terrier (1)  ·  Carol A Langford, MD, MHS (1)  ·  Caroline OS Savage (1)

Results publications

PMID 10068416, PMID 12401245, PMID 12905485, PMID 15751091, PMID 15838068, PMID 15986348, PMID 16221103, PMID 16378799, PMID 16646004, PMID 16914703, PMID 17332971, PMID 17407214, PMID 17557758, PMID 19451574, PMID 20054700, PMID 20647199, PMID 22127969, PMID 22975753, PMID 23290985, PMID 23305955, PMID 23528439, PMID 23754238, PMID 23897775, PMID 23901839, PMID 23902481, PMID 24572997, PMID 25047592, PMID 25372085, PMID 25776953, PMID 26387933, PMID 26621483, PMID 27049404, PMID 27310969, PMID 27696762, PMID 27924855, PMID 28270229, PMID 28514601, PMID 28592297, PMID 28605168, PMID 28678392, PMID 28745999, PMID 29386515, PMID 29695500, PMID 29724729, PMID 30612116, PMID 30666823, PMID 30786937, PMID 30835950, PMID 31056661, PMID 31216123

NIH funding

2016 (3), 2009 (2), 2014 (2), U54AR057319 (2), 2017 (1), 2018 (1), 2023 (1), R01HL033233 (1), R01HL115041 (1)